XDC with WuXi Bio_4C

About Us

WuXi XDC, a WuXi Biologics subsidiary, is a joint venture between WuXi Biologics and the WuXi AppTec subsidiary, WuXi STA, providing end-to-end contract development and manufacturing of bioconjugates including antibody-drug conjugates (ADCs).  Our open access bioconjugation platform accelerates and transforms the discovery, development, and manufacturing of bioconjugates, ‘Linking innovation to health’, enabling our global healthcare partners and benefiting patients worldwide, with the most comprehensive capabilities and technologies in the biologics industry.

WuXi XDC greatly simplifies Antibody Drug Conjugate (ADC) and other bioconjugate drug development by providing all preclinical activities, holistic and integrated CMC development process and the entire supply chain under one company and in one centralized region.  WuXi XDC combines its existing single-source development and manufacturing platforms for payload, linker, and biologics (e.g., monoclonal, or bispecific antibodies or other recombinant proteins) with the company’s leading bioconjugation development technology platforms and previously established drug substance and drug product GMP manufacturing facilities.

Find out more about us in our Resources Library. 

Passport Stamp for World ADC San Diego 2022

Passport 2022 SD (3)